News

FDA Approves Israeli Cancer-Freezing Technology

IceCure’s cancer-freezing technology relies on an innovative process referred to as cryoablation therapy.

Published

5 years ago

April 8, 2021

Joanna Melki

fda approves israeli cancer-freezing technology

Shutterstock

Israeli healthtech companies and researchers have developed many life-saving technologies, some of which are now used in hospitals around the world. One highly promising medical technology has just been approved by the United States Food and Drug Administration (FDA) after demonstrating its ability to eliminate tumors using new cancer-freezing technology.

The groundbreaking technology comes from a healthtech company called IceCure. The company was founded in 2006, and it’s currently headquartered in the coastal city of Caesarea, Israel.

IceCure’s cancer-freezing technology relies on an innovative process referred to as cryoablation therapy. The goal of cryoablation is to insert a hollow needle into the breast until the tumor is reached. Liquid nitrogen is then precisely applied directly into a tumor to kill the abnormal tissue by freezing it at a very low temperature of -170°C (-274 F).

“We are basically covering the tissue with an ice ball. No tissue can survive such a low temperature,” explained Tlalit Bussi Tel-Tzure, vice president of business development and global marketing at IceCure. “Once the tissue is dead, it will dissolve in the body in a natural process and be absorbed in the body in a couple of weeks.”

The technology has already proved to be extremely successful when it comes to destroying kidney tumors, demonstrating perfect efficiency. Its main advantage is the fact that it can be carried out either at a doctor’s office or an outpatient facility thanks to its minimally invasive nature. The entire procedure can take less than one hour from start to finish, and it doesn’t leave any lasting physical mark on the body.

Also Read: Israelis Have Successfully Grown Mouse Embryos In Artificial Wombs

“Our main vision is to become the gold standard in breast cancer treatment,” said Eyal Shamir, CEO of IceCure Medical. “Most of the cases where you have good early detection are small tumors, considered early stage, and the only treatment available today is surgery.”

IceCure isn’t the only company exploring the application of cryoablation for treating breast cancer. There’s also California-based Sanarus Technologies, which has recently completed a clinical trial in the United States.

News

At I/O 2026, Sundar Pichai Concedes AI Must Deliver Real Value

Gemini 3.5, a personal agent called Spark, agentic shopping, and Android XR eyewear are all aimed at making AI feel useful, not just impressive.

Published

2 weeks ago

May 20, 2026

Nour Nasir

at io 2026 sundar pichai concedes ai must deliver real value

Google

Google’s annual I/O developer conference (I/O 2026) has recently become a status update on the same question: can the company turn its AI spending into products people use every day? This year, chief executive Sundar Pichai described Google as being in a phase of hyper progress, while conceding this is the part of the cycle where people want to see real value in the products they use on a day-to-day basis.

The strategy on display was to push agents — AI systems that act on a user’s behalf — into nearly every Google product at once. Search now has an “intelligent search box” that returns generated explainer videos alongside links. Gmail, Docs, YouTube and Maps are gaining their own agent layers, including a Docs Live feature that turns spoken instructions into drafted text with citations.

Two new models, Gemini 3.5 and a cheaper Gemini 3.5 Flash, arrived the same day. Google says 900 million people now use Gemini, and that more than 50 billion images have been generated with it. The pricing tier names are likely to confuse buyers: a new AI Ultra plan launches at $100 a month, while the older Gemini AI Ultra drops from $250 to $200.

The flashier announcements were Gemini Omni, a video generator pitched as a more realistic answer to OpenAI’s discontinued Sora 2, and Gemini Spark, a personal agent that handles recurring tasks across a user’s Google account. A new universal shopping cart lets agents complete purchases across multiple retailers from inside Google itself, placing the company between the merchant and the buyer, and also owning the checkout.

Also Read: DJI Teases Dual-Camera Osmo Pocket 4P For 2026 Launch

Google also confirmed its Android XR eyewear, built with Samsung and frames from Warby Parker and Gentle Monster. Audio-only glasses ship this autumn; a display-equipped version, which would superimpose live translations into the wearer’s field of view, is still in development. Both sets translate, however only the display version shows you the result.

What Pichai did not resolve is the bargain underneath all this. An agent is only useful to the degree it knows your calendar, your inbox, your shopping history and your physical surroundings. Google has now confirmed that, in time, the same context may carry advertising.